NGM Biopharmaceuticals (NGM) PT Raised to $35 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst Matthew Luchini raised the price target on NGM Biopharmaceuticals (NASDAQ: NGM) to $35.00 (from $29.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
